Diabetes

Evolocumab safe, effective for those with dysglycemia, MetS

(HealthDay)—For patients with or without dysglycemia or metabolic syndrome (MetS), evolocumab is safe and efficacious for reducing low-density lipoprotein cholesterol at 52 weeks, according to research published online ...

Cardiology

China facing epidemic of heart disease, stroke

A 20-year rise in cardiovascular disease (CVD) in China appears to have been spurred largely by increases in high blood pressure, according to a new study from Harvard T.H. Chan School of Public Health. Increasing body mass ...

Oncology & Cancer

Research points to a new treatment for pancreatic cancer

Researchers have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis, pointing to a potential new treatment using drugs previously developed for atherosclerosis.

Health

Sleep loss detrimental to blood vessels

Lack of sleep has previously been found to impact the activation of the immune system, inflammation, carbohydrate metabolism and the hormones that regulate appetite. Now University of Helsinki researchers have found that ...

Oncology & Cancer

Metabolic syndrome up with ADT in prostate cancer

(HealthDay)—For patients with prostate cancer treated with androgen deprivation therapy there are increases in components of metabolic syndrome and in the prevalence of full metabolic syndrome, according to a study published ...

page 6 from 16